Accueil   Diary - News   All news Focus on Alizé Pharma

Focus on Alizé Pharma

Alizé Pharma, a company member of Lyonbiopole,announces that it has raised €1.8 million (USD $1.94 million) in a first financing round. The funding round was supported by a syndicate of investors that included Sofimac Partners via their FCPI Emergence Innovation 1 seed capital fund, Octalfa, Sham Innovation Santé, Rhône-Alpes Création, Crédit Agricole Création, CEMA and TAB Consulting.

Alizé Pharma III will use the funds to conduct a pharmacology and lead optimization program on a family of peptides with anabolic effects on the bone. The I-HBD1 program will be performed in collaboration with Alizé Pharma III’s US partner New Paradigm Therapeutics Inc., a spin-off from the University of North Carolina at Chapel Hill founded by Dr. David Clemmons. The aim of the program is to select a drug candidate that will enter development for the treatment of osteoporosis and other diseases with impaired bone metabolism in 2016.

 

Read the press release

 

 Alizé Pharma is a group of companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The management is a team of drug development experts. The board of directors has a breadth of international experience. Its business strategy is to advance programs based on medical innovation to the clinical stage and establish partnerships with pharmaceutical companies to secure both short- and long-term revenue streams. Since its creation in 2007 the group has raised €15.1 million from private and institutional investors. It has advanced two programs to the clinical phase and has also signed its first industrial partnership. Alizé Pharma SAS is working on a peptide derived from unacylated ghrelin (AZP- 531). This program is in Phase II clinical development for the treatment of Prader-Willi syndrome and in Phase Ib for type 2 diabetes. Alizé Pharma II SAS is focusing on the development of ASPAREC®, a new pegylated recombinant L-asparaginase for the treatment of acute lymphoblastic leukemia (ALL). It is partnered with Jazz Pharmaceuticals (Nasdaq: JAZZ) and is currently in Phase II/III clinical development. Founded in 2014, Alizé Pharma III SAS has acquired exclusive worldwide rights to develop and commercialize a family of new peptides with bone anabolic properties.
www.alz-pharma.com